Key result
Catheter-based substrate modification using voltage mapping significantly reduced median ventricular tachycardias from 1.6 to 0.2 per month in patients with an old myocardial infarction and an ICD.
Why the study?
Does catheter-based substrate modification using voltage mapping reduce ventricular tachycardia and device therapy in patients with old myocardial infarction and an implantable cardioverter defibrillator?
Observational (n=27)
No
Does catheter-based substrate modification using voltage mapping reduce ventricular tachycardia and device therapy in patients with old myocardial infarction and an implantable cardioverter defibrillator?
Answers are grounded in this paper and cite their sources.
Catheter-based substrate modification using voltage mapping significantly reduces the burden of ventricular tachycardia and ICD shocks in patients with prior myocardial infarction.
PURPOSE: The frequent occurrence of ventricular tachycardia can create a serious problem in patients with an implantable cardioverter defibrillator. We assessed the long-term efficacy of catheter-based substrate modification using the voltage mapping technique of infarct-related ventricular tachycardia and recurrent device therapy. METHODS: The study population consisted of 27 consecutive patients (age 68 ± 8 years, 25 men, mean left ventricular ejection fraction 31 ± 9%) with an old myocardial infarction and multiple and/or hemodynamically not tolerated ventricular tachycardia necessitating repeated device therapy. A total of 31 substrate modification procedures were performed using the three-dimensional electroanatomical mapping system. Patients were followed up for a median of 23.5 (interquartile range 6.5-53.2) months before and 37.8 (interquartile range 11.7-71.8) months after ablation. Antiarrhythmic drugs were not changed after the procedure, and were stopped 6 to 9 months after the procedure in patients who did not show ventricular tachycardia recurrence. RESULTS: Median ventricular tachycardias were 1.6 (interquartile range 0.7-6.7) per month before and 0.2 (interquartile range 0.00-1.3) per month after ablation (P = 0.006). Nine ventricular fibrillation episodes were registered in seven patients before and two after ablation (P = 0.025). Median antitachycardia pacing decreased from 1.6 (interquartile range 0.01-5.5) per month before to 0.18 (interquartile range 0.00-1.6) per month after ablation (P = 0.069). Median number of shocks decreased from 0.19 (interquartile range 0.04-0.81) per month before to 0.00 (interquartile range 0.00-0.09) per month after ablation (P = 0.001). One patient had a transient ischemic attack during the procedure, and another developed pericarditis. Nine patients died during follow-up, eight patients due to heart failure and one patient during valve surgery. CONCLUSION: Catheter-based substrate modification using voltage mapping results in a long-lasting reduction of cardioverter defibrillator therapy in patients with multiple and/or hemodynamically not tolerated infarct-related ventricular tachyarrhythmia.
No takes yet. Share an insight, caveat, or question.
Alzand et al. (2011) conducted an observational in Unmappable ventricular tachycardia after an old myocardial infarction (n=27). Catheter-based substrate modification using voltage mapping vs. Pre-ablation baseline was evaluated on Median ventricular tachycardias per month (p=0.006). Catheter-based substrate modification using voltage mapping significantly reduced median ventricular tachycardias from 1.6 to 0.2 per month in patients with an old myocardial infarction and an ICD.
Synapse has enriched 10 related papers. Consider them for comparative context: